JP4989976B2 - 翻訳開始阻害剤としての３−３−二置換オキシインドール - Google Patents

翻訳開始阻害剤としての３−３−二置換オキシインドール Download PDF

Info

Publication number
JP4989976B2
JP4989976B2 JP2006553263A JP2006553263A JP4989976B2 JP 4989976 B2 JP4989976 B2 JP 4989976B2 JP 2006553263 A JP2006553263 A JP 2006553263A JP 2006553263 A JP2006553263 A JP 2006553263A JP 4989976 B2 JP4989976 B2 JP 4989976B2
Authority
JP
Japan
Prior art keywords
compound
formula
pharmaceutical composition
group
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006553263A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007522234A (ja
Inventor
ジョゼ エー． ハルペリン
アマーナス ナタラジャン
フセイン アクタス
ユン‐ファ ファン
ハン チェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of JP2007522234A publication Critical patent/JP2007522234A/ja
Application granted granted Critical
Publication of JP4989976B2 publication Critical patent/JP4989976B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
JP2006553263A 2004-02-13 2005-02-11 翻訳開始阻害剤としての３−３−二置換オキシインドール Expired - Fee Related JP4989976B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54438404P 2004-02-13 2004-02-13
US60/544,384 2004-02-13
PCT/US2005/004373 WO2005080335A1 (en) 2004-02-13 2005-02-11 3-3-di-substituted-oxindoles as inhibitors of translation initiation

Publications (2)

Publication Number Publication Date
JP2007522234A JP2007522234A (ja) 2007-08-09
JP4989976B2 true JP4989976B2 (ja) 2012-08-01

Family

ID=34886031

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006553263A Expired - Fee Related JP4989976B2 (ja) 2004-02-13 2005-02-11 翻訳開始阻害剤としての３−３−二置換オキシインドール

Country Status (6)

Country Link
US (6) US7737172B2 (US08088816-20120103-C00013.png)
EP (1) EP1718611A4 (US08088816-20120103-C00013.png)
JP (1) JP4989976B2 (US08088816-20120103-C00013.png)
AU (1) AU2005214338B2 (US08088816-20120103-C00013.png)
CA (1) CA2555812A1 (US08088816-20120103-C00013.png)
WO (1) WO2005080335A1 (US08088816-20120103-C00013.png)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
JP2007532496A (ja) * 2004-04-08 2007-11-15 トポターゲット・アクティーゼルスカブ ジフェニルオキソ−インドール−２−オン化合物および癌の処置におけるそれらの使用
WO2005113513A2 (en) 2004-05-12 2005-12-01 Chemocentryx Aryl sulfonamides
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP2491926B1 (en) 2005-03-22 2018-05-09 President and Fellows of Harvard College Treatment of protein degradation disorders
MX2008010462A (es) 2006-02-14 2009-04-17 Harvard College Inhibidores de histona desacetilasa.
CN101400362B (zh) 2006-02-14 2016-10-12 哈佛大学校长及研究员协会 双官能组蛋白去乙酰化酶抑制剂
CA2654540C (en) 2006-05-03 2017-01-17 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
AU2008240599A1 (en) * 2007-04-24 2008-10-30 Topotarget A/S Substituted 3-(4-hydroxyphenyl)-indolin-2-one-compounds
RU2515611C2 (ru) 2008-07-23 2014-05-20 Президент Энд Феллоуз Оф Гарвард Колледж Ингибиторы деацетилазы и их применение
WO2010109008A1 (en) 2009-03-26 2010-09-30 Topotarget A/S Prodrugs of substituted 3-(4-hydroxyphenyl)-indolin-2-ones
AU2010253820A1 (en) 2009-05-28 2011-12-22 President And Fellows Of Harvard College N,N-diarylurea compounds and N,N'-diarylthiourea compounds as inhibitors of translation initiation
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
CN102127002B (zh) * 2011-01-20 2012-06-27 华东师范大学 一种制备3,3-二芳基取代和3-烷基-3-芳基取代氧化吲哚衍生物的方法
WO2014047437A1 (en) * 2012-09-20 2014-03-27 President And Fellows Of Harvard College 3-3-di-substituted-oxindoles as inhibitors of translation initiation
WO2014113820A1 (en) * 2013-01-18 2014-07-24 Shapiro David J Estrogen receptor inhibitors
US10420761B2 (en) 2013-03-15 2019-09-24 University Of Florida Research Foundation, Inc. Allosteric inhibitors of thymidylate synthase
US9718775B2 (en) 2014-03-14 2017-08-01 Milliken & Company Oxindole compounds and compositions comprising the same
KR102496364B1 (ko) * 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Ｓｍｙｄ 억제제
US10076267B2 (en) 2014-10-03 2018-09-18 General Electric Company Methods and systems for improved navigation
AR105025A1 (es) * 2015-06-19 2017-08-30 Astellas Pharma Inc Compuesto de imidazodiazepina
US10835524B2 (en) 2015-06-24 2020-11-17 University Of Florida Research Foundation, Incorporated Compositions for the treatment of pancreatic cancer and uses thereof
MA53105A (fr) * 2018-07-03 2021-05-12 Univ Illinois Activateurs de la réponse à une protéine non dépliée
CN114621130A (zh) * 2019-11-01 2022-06-14 Fmc公司 用于合成2-氨基-5-氯-n,3-二甲基苯甲酰胺的高效新方法
CN113548999B (zh) * 2020-04-24 2023-04-28 复旦大学 消旋和手性3-(2,3-丁二烯基)氧化吲哚酮类化合物及制备方法及应用
WO2021222738A1 (en) * 2020-05-01 2021-11-04 The Board Of Trustees Of The University Of Illinois Compounds for estrogen receptor positive cancers
EP3912625A1 (en) * 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
WO2022047375A1 (en) * 2020-08-31 2022-03-03 Trustees Of Boston University Novel fungal modulators
CN114057624B (zh) * 2021-12-10 2023-09-12 贵州大学 一种茶香酮拼接氧化吲哚类化合物及其制备方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES426436A1 (es) 1974-05-18 1976-07-01 Andreu Sa Dr Procedimiento para la obtencion de derivados de la 3,3-bis (4-hidroxifenil)-2-indolinona.
JPS55129284A (en) * 1979-03-27 1980-10-06 Shionogi & Co Ltd 3-(1-imipazolyl)indolin-2-one
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
SU1823440A1 (ru) 1990-10-18 1996-11-20 Киевский научно-исследовательский филиал Государственного научно-исследовательского и проектного института хлорной промышленности N-производные 3,3-бис-(4-оксиарил)индолин-2-она в качестве модификаторов поликарбоната
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
JPH07301916A (ja) 1994-04-28 1995-11-14 Nippon Zeon Co Ltd ポジ型レジスト組成物
JPH08183853A (ja) 1994-12-28 1996-07-16 Nippon G Ii Plast Kk ポリカーボネート、ポリカーボネート組成物およびこれらの製造方法
DE19638888A1 (de) 1996-09-23 1998-03-26 Bayer Ag Cokatalysatoren für die Bisphenolsynthese
JP4035286B2 (ja) 2000-12-11 2008-01-16 本州化学工業株式会社 イサチンビス（ｏ−クレゾール）の製造方法
JP4035287B2 (ja) 2000-12-11 2008-01-16 本州化学工業株式会社 イサチンビス（ｏ−クレゾール）の製造方法
JP2003176269A (ja) * 2001-12-12 2003-06-24 Mitsubishi Pharma Corp 環状アミド化合物およびその医薬用途
DE10202874A1 (de) 2002-01-25 2003-08-07 Basf Ag Verfahren zur Herstellung von 3,3-Bis-(4-hydroxyaryl)- oxindolen
US7250442B2 (en) * 2002-03-15 2007-07-31 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
JP2007532496A (ja) * 2004-04-08 2007-11-15 トポターゲット・アクティーゼルスカブ ジフェニルオキソ−インドール−２−オン化合物および癌の処置におけるそれらの使用
JP2008528634A (ja) 2005-01-31 2008-07-31 セプション・セラピューティクス・インコーポレーテッド 腫瘍壊死因子インヒビター
US20100029646A1 (en) 2006-12-11 2010-02-04 Topo Target A/S Prodrugs of diphenyl ox-indol-2-one compounds
AU2008240599A1 (en) 2007-04-24 2008-10-30 Topotarget A/S Substituted 3-(4-hydroxyphenyl)-indolin-2-one-compounds

Also Published As

Publication number Publication date
US20070099976A1 (en) 2007-05-03
US7737172B2 (en) 2010-06-15
US8354440B2 (en) 2013-01-15
US20120077759A1 (en) 2012-03-29
EP1718611A4 (en) 2009-09-23
US20110046367A1 (en) 2011-02-24
US20100256388A1 (en) 2010-10-07
US8044089B2 (en) 2011-10-25
JP2007522234A (ja) 2007-08-09
US8268879B2 (en) 2012-09-18
AU2005214338A1 (en) 2005-09-01
US20100249201A1 (en) 2010-09-30
US7846962B2 (en) 2010-12-07
EP1718611A1 (en) 2006-11-08
US8088816B2 (en) 2012-01-03
WO2005080335A1 (en) 2005-09-01
CA2555812A1 (en) 2005-09-01
US20090299058A1 (en) 2009-12-03
AU2005214338B2 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
JP4989976B2 (ja) 翻訳開始阻害剤としての３−３−二置換オキシインドール
EP1956910B1 (en) Oncogenic ras-specific cytotoxic compound and methods of use thereof
WO2021114864A1 (zh) 基于pH和GSH双重响应的β-咔啉-环烯酮衍生物及其用途
JP6654197B2 (ja) インドリノン化合物及びその使用
CN101128423A (zh) 新型脂氧化酶抑制剂
US8304421B2 (en) Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents
EP2784061B1 (en) Acyl-hydrazone and oxadiazole compounds, pharmaceutical compositions containing the same and uses thereof
US10450295B2 (en) Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis
US20080200557A1 (en) Method for Inhibiting Lipid Peroxidation
WO2018076537A1 (zh) D-3-磷酸甘油酸脱氢酶别构抑制剂及其应用
US11730712B2 (en) Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
KR101965348B1 (ko) N'-히드록시인다졸카르복시이미다미드 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용가능한 염, 및, 이를 유효성분으로 포함하는 항암용 조성물
US8133913B2 (en) Substituted indeno [1,2-b]indole derivatives as novel inhibitors of protein kinase CK2 and their use as tumor therapeutic agents, cytostatics and diagnostic aids

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20101102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110301

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110519

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120111

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120402

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120501

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150511

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees